Gilteritinib (Xospata): FLT3-Mutated AML Treatment
Gilteritinib acts like a precision missile designed to destroy one of the most aggressive forms of leukemia. In many patients with Acute Myeloid Leukemia (AML), a mutation in the FLT3 gene acts like a "stuck gas pedal," forcing cancer cells to divide uncontrollably.
Gilteritinib (Xospata) releases this pedal. It specifically inhibits the FLT3 receptor, cutting off the tumor's growth signal. This offers a vital lifeline to patients whose cancer has returned after standard chemotherapy or never responded in the first place.
As an oral therapy, it allows patients to fight this severe disease from home, maintaining a better quality of life.
Indications
- Acute Myeloid Leukemia (AML): Treatment of adult patients with relapsed or refractory AML.
- Crucial Requirement: Effective only in patients with a confirmed FLT3 mutation (ITD or TKD). A companion diagnostic test is mandatory before starting therapy to ensure the drug targets the right mutation.
Dosage and administration
The daily intake involves multiple tablets.
- Standard Dose: 120 mg once daily. Since tablets are typically 40 mg, this means taking 3 tablets at once.
- Instructions: Swallow tablets whole with water. They can be taken with or without food. Consistency is key—try to take them at the same time every day.
- Missed Dose: If you miss a dose by more than 12 hours, skip it and wait for the next scheduled time. Do not double up.
- Hypersensitivity to Gilteritinib.
- Congenital Long QT Syndrome (heart rhythm disorder).
- Pregnancy and breastfeeding (severe risk to the fetus).
- Severe hepatic impairment.
Regular monitoring is essential due to the drug's potency.
- Liver (Very Common): Elevated liver enzymes (ALT/AST). Your doctor will check this via blood tests.
- Muscles: Muscle pain, joint pain, and elevated CPK levels.
- Differentiation Syndrome: A rare but serious condition where cancer cells rapidly mature, causing fever and shortness of breath. Seek medical help immediately if this occurs.
- Neurological: Dizziness, rarely posterior reversible encephalopathy syndrome (PRES).
List of medicines by active substance Gilteritinib
✅ All products loaded (1)